Stockscreener 앱 받기
1.9295
3.10%
-0.0605
전일 마감가:
$1.99
열려 있는:
$2.04
하루 거래량:
138.80K
Relative Volume:
0.12
시가총액:
$393.98M
수익:
$889.00K
순이익/손실:
$-156.28M
주가수익비율:
-3.6634
EPS:
-0.5267
순현금흐름:
$-150.06M
1주 성능:
-5.48%
1개월 성능:
+7.13%
6개월 성능:
-20.32%
1년 성능:
+217.94%
1일 변동 폭
$1.90
$2.04
1주일 범위
$1.87
$2.206
52주 변동 폭
$1.02
$7.13
Prokidney Corp Stock (PROK) Company Profile
명칭
Prokidney Corp
전화
336-999-7028
주소
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.92 | 418.61M | 889.00K | -156.28M | -150.06M | -0.5267 |
VRTX
Vertex Pharmaceuticals Inc
|
516.77 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
661.66 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
927.39 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
316.62 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
188.40 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-16 | 개시 | H.C. Wainwright | Buy |
| 2025-06-30 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-09-30 | 개시 | JP Morgan | Neutral |
| 2024-09-10 | 개시 | Guggenheim | Buy |
| 2024-03-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-01-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-07-25 | 개시 | BTIG Research | Buy |
| 2022-12-21 | 개시 | Jefferies | Buy |
| 2022-11-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-10-18 | 개시 | UBS | Buy |
| 2022-10-14 | 개시 | Citigroup | Buy |
| 2022-09-23 | 개시 | BofA Securities | Buy |
| 2022-09-02 | 개시 | Evercore ISI | Outperform |
모두보기
Prokidney Corp 주식(PROK)의 최신 뉴스
ProKidney Corp.(NasdaqCM: PROK) added to Russell 2000 Index - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell Microcap Value Benchmark Index - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell 2000 Value Benchmark - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell Microcap Growth Benchmark Index - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell 2000 Growth Benchmark - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell Microcap Index - marketscreener.com
Price to earnings forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Price to earnings forward of ProKidney Corp. Class A – BMV:PROK - TradingView
Price to sales forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Enterprise value to revenue forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Enterprise value to EBIT forward of ProKidney Corp. Class A – BMV:PROK - TradingView
Enterprise value to EBITDA forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Price to sales forward of ProKidney Corp. Class A – BMV:PROK - TradingView
ProKidney Corp (PROK) Valuation: PE, PB & Fair Value Analysis - TradingKey
ProKidney Corp. Class A Actuals & Estimates (NASDAQ:PROK) - TradingView
ProKidney Corp. (PROK) Faces Selling Pressure Near Resistance – Key Levels in FocusDouble EMA - dars.gov.et
PROK Forecast — Price Target — Prediction for 2027 - TradingView
ProKidney (PROK) Study Update Summary - Quartr
ProKidney Corp (PROK) Institutional Confidence - TradingKey
ProKidney Corp (PROK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProKidney Corp (PROK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ProKidney Corp (PROK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PROK Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
ProKidney Corp (PROK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path - Yahoo Finance
ProKidney Corp (PROK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProKidney Corp (PROK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ProKidney Corp (PROK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ProKidney (NASDAQ: PROK) legal chief converts paired units to Class A stock - Stock Titan
ProKidney Corp. (PROK) Q1 2026 Earnings: Narrow EPS Beat Amid Clinical ProgressOperating Margin Analysis - newsline.com
[Form 3] PROKIDNEY CORP. Initial Statement of Beneficial Ownership - Stock Titan
Identiv And Two Other Penny Stocks To Watch Closely - simplywall.st
PROK: Phase III cell therapy for advanced CKD targets dialysis delay, with pivotal data due in 2027 - TradingView
ProKidney appoints Kenneth Locke as chief technical officer - The Pharma Letter
ProKidney names first chief technology officer as kidney therapy nears pivotal trial readout - The Business Journals
ProKidney expands executive management team with chief technical officer - Winston-Salem Journal
Prokidney Corp. Announces Appointment of Kenneth Locke as Chief Technical Officer - marketscreener.com
ProKidney names Kenneth Locke as chief technical officer By Investing.com - Investing.com Australia
ProKidney Corp. Appoints Kenneth Locke as Chief Technical Officer - geneonline.com
ProKidney names Kenneth Locke as chief technical officer - Investing.com
ProKidney Appoints Kenneth Locke as Chief Technical Officer - The Manila Times
ProKidney shareholders reaffirm board and auditor at 2026 meeting - The Globe and Mail
PROKIDNEY CORP. (PROK) director receives 135,000 stock options grant - Stock Titan
Director at PROKIDNEY CORP. (PROK) receives 135,000 stock options as compensation - Stock Titan
ProKidney (PROK) director receives 135,000 stock options grant as compensation - Stock Titan
ProKidney (PROK) director awarded 135K stock options as compensation - Stock Titan
ProKidney (NASDAQ: PROK) grants 135,000 stock options to director - Stock Titan
[Form 4] PROKIDNEY CORP. Insider Trading Activity - Stock Titan
PROKIDNEY (NASDAQ: PROK) director receives 135,000 stock options as equity award - Stock Titan
ProKidney (NASDAQ: PROK) 2026 meeting backs board nominees and EY - Stock Titan
ProKidney Corp. (PROK) Edges Higher Amid Continued Support: Potential for Breakout Above $1.94 ResistanceCombination Correction - The Legal Advocate
Prokidney Corp (PROK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Prokidney Corp 주식 (PROK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Pereira Brian JG | Director |
Nov 12 '25 |
Sale |
2.72 |
255,026 |
694,515 |
54,333 |
1.95%
0.07%
자본화:
|
볼륨(24시간):